Neuoryx is an early-stage Alzheimer's biomarker and AI research initiative, developing and evaluating investigational blood-based biomarker workflows for research. The project studies whether selected blood-based markers — tau, amyloid, and glial-response proteins — together with AI-assisted analysis, can support future research workflows for earlier biological understanding of neurodegenerative disease.
Neuoryx is an investigational research project. It is not a cleared, approved, or commercially available diagnostic test, and is not intended to diagnose Alzheimer's disease, predict disease risk, guide treatment, replace physician evaluation, or support clinical decision-making. All biomarker references on this site are provided for research and scientific-context purposes only.
Blood-based tau, amyloid, and glial markers have drawn intense scientific interest for Alzheimer's research. Yet measuring them reliably, and understanding the earliest biology, remains an open area of study — which is where this initiative focuses.
Spinal-fluid sampling and amyloid PET remain research and clinical reference standards, but their invasiveness limits their use in large-scale, longitudinal biomarker studies.
Alzheimer's-related proteins circulate at very low concentrations. Achieving robust, reproducible measurement from small blood volumes remains an open analytical challenge worth studying.
The preclinical and early phases of the disease are where biological understanding is thinnest — and where accessible, well-characterized research assays could contribute the most.
Neuoryx is evaluating a research-stage workflow that combines sample preparation, multiplex biomarker sensing, quantitative readout, and structured data interpretation — as a scientific investigation, not a clinical service.
The research workflow explores how small-volume blood samples may be processed for biomarker assay development in a laboratory setting.
The investigational assay is being designed to study selected Alzheimer's-related biomarkers — pTau217, Aβ42, Aβ40, and GFAP — in a research context.
The platform aims to generate structured research outputs that support analytical validation, study design, and future translational research. It is not intended to provide clinical diagnosis or treatment guidance.
The biomarkers under investigation span both biological axes of Alzheimer's — the tau–amyloid pathology and the glial response that rises early alongside it.
The field has clarified which biomarkers matter. Neuoryx is a research effort exploring how they might be measured through more accessible assay workflows — as a scientific question, not a clinical product. These references describe the surrounding scientific landscape, not the performance of any Neuoryx work.
A staged research route, from feasibility through analytical validation and into translational research planning.
Evaluate assay design, biomarker selection, workflow assumptions, and early prototype feasibility in a research environment.
Study assay performance, reproducibility, sensitivity, specificity, and workflow reliability using appropriate research samples and controls.
Use evidence from feasibility and analytical validation to determine whether future clinical, regulatory, or translational pathways should be explored.
Neuoryx is currently a research-stage initiative. Any future clinical or commercial use would require appropriate validation, ethics review, regulatory review, and applicable approvals.
Neuoryx welcomes collaboration from researchers, scientists, clinicians, engineers, students, academic institutions, laboratories, patient advocates, and organizations interested in advancing responsible Alzheimer's and neurodegenerative disease research.
We invite contributors from around the world to share expertise, ideas, research methods, datasets, protocols, validation approaches, and collaborative study opportunities that may help strengthen this early-stage scientific initiative.
Neuoryx is a research-only initiative. It is not currently offering diagnostic testing, clinical services, treatment recommendations, or patient-specific medical advice.
Tell us how you'd like to contribute. We read every message.